Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
Stifel 2020
Date: | |
Time: | |
Format: | Presentation |
A live audio webcast of the presentation will be available in the Investors section on the Company’s website at www.cidara.com.
3rd Annual
Date: | |
Time: | |
Format: | Panel Discussion - No Fungus Among Us: Addressing an Important Fungal Need |
About
Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in
INVESTOR CONTACT:
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Karen O’Shea, Ph.D.
(929) 469-3860
koshea@lifescicomms.com
Source: Cidara Therapeutics, Inc.